Karyopharm Therapeutics reported $21.46M in Gross Profit on Sales for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
TG Therapeutics TGTX:US 1.4M 743K
Abbott ABT:US $ 5276M 780M
Amgen AMGN:US $ 4889M 478M
AstraZeneca AZN:LN 6.03B 627M
Astrazeneca AZN:US 6.03B 627M
Biocryst Pharmaceuticals BCRX:US $ 49.62M 36.44M
Bristol Myers Squibb BMY:US $ 9252M 682M
Eli Lilly And LLY:US $ 4786.9M 140.1M
Epizyme EPZM:US $ 10.52M 5.74M
GlaxoSmithKline GSK:LN 5.57B 566M
Johnson & Johnson JNJ:US $ 15725M 440M
Karyopharm Therapeutics KPTI:US $ 21.46M 864K
MacroGenics MGNX:US 30.74M 13.87M
Merk MRK:US $ 8718M 93M
Nektar Therapeutics NKTR:US $ 20.66M 2.77M
Novartis NOVN:VX 9.54B 679M
Novartis NVS:US $ 9540M 679M
Pfizer PFE:US $ 11985M 1575M
Regeneron Pharmaceuticals REGN:US $ 4444.8M 2224.1M
Ultragenyx Pharmaceutical RARE:US $ 83.84M 10.37M
YTE INCY:US $ 673.08M 92.18M